Ho L T, Chern J C, Hsu S C, Chen R L, Kwok C F, Wu M S, Chen J J, Jap T S
Proc Natl Sci Counc Repub China B. 1985 Jan;9(1):20-9.
Pentaerythritol tetranicotinate (Perycit), at an oral dosage of 750 mg daily, was given to 12 patients with idiopathic hyperlipidemia and to 12 patients with hyperlipidemia superimposed with diabetes mellitus (DM). With 2 months off-drug period as the baseline, each patient then received 3 months of placebo and 3 months of Perycit. The sequence of treatment was randomized and balanced in frequency. Blood glycosylated hemoglobin (Hb A1) and fasting plasma glucose (FPG) were used as indices of diabetic control. Serum triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and TC/HDL-C ratio were measured and calculated in order to compare the antilipemic effectiveness of Perycit with that of placebo. The non-parametric Wilcoxon test was used for the statistical analysis. The results showed that in the idiopathic group, Perycit significantly lowered the serum level of TG and the ratio of TC/HDL-C, and elevated the serum level of HDL-C. In the diabetic group, although there was a similar improvement in diabetic control in both periods of placebo and Perycit treatments, there was no change in the serum levels of TG and HDL-C. There was a slight increase of the serum levels of TC in the periods of Perycit treatment, whereas a small increase of HDL-C resulted in a mild decrease of the TC/HDL-C ratio. There was mild and transient facial flushing during the Perycit treatment in 6 out of 12 diabetic patients. Otherwise, there was no side effects in either group. Pooling the two groups' data together, Perycit increased the serum levels of HDL-C and decreased the TC/HDL-C ratio. It is concluded that Perycit has antilipemic effects in patients with idiopathic hyperlipidemia, and may be helpful in reducing the atherogenic risks in these patients. In patients with hyperlipidemia superimposed with DM, although the serum lipids composition was not significantly changed after Perycit, the atherogenic risks might also be reduced as demonstrated by the decrease of the TC/HDL-C ratio.
每天口服750毫克的烟酸季戊四醇酯（心脉乐），给予12例特发性高脂血症患者和12例合并糖尿病的高脂血症患者。以停药2个月作为基线，然后每位患者接受3个月的安慰剂治疗和3个月的心脉乐治疗。治疗顺序随机且频率均衡。糖化血红蛋白（Hb A1）和空腹血糖（FPG）用作糖尿病控制指标。测量并计算血清甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）以及TC/HDL-C比值，以比较心脉乐与安慰剂的降脂效果。采用非参数Wilcoxon检验进行统计分析。结果显示，在特发性高脂血症组，心脉乐显著降低了血清TG水平和TC/HDL-C比值，并升高了血清HDL-C水平。在糖尿病组，虽然安慰剂治疗期和心脉乐治疗期的糖尿病控制情况有相似改善，但血清TG和HDL-C水平没有变化。在心脉乐治疗期血清TC水平略有升高，而HDL-C的小幅升高导致TC/HDL-C比值轻度降低。12例糖尿病患者中有6例在心脉乐治疗期间出现轻度且短暂的面部潮红。除此之外，两组均未出现副作用。将两组数据合并后，心脉乐升高了血清HDL-C水平并降低了TC/HDL-C比值。结论是，心脉乐对特发性高脂血症患者有降脂作用，可能有助于降低这些患者的动脉粥样硬化风险。在合并糖尿病的高脂血症患者中，虽然心脉乐治疗后血清脂质成分没有显著变化，但TC/HDL-C比值的降低表明动脉粥样硬化风险也可能降低。
